IOBT vs. RNAC, ANIX, EBS, PDSB, BRNS, ORMP, CLRB, MCRB, GNLX, and INCR
Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Cartesian Therapeutics (RNAC), Anixa Biosciences (ANIX), Emergent BioSolutions (EBS), PDS Biotechnology (PDSB), Barinthus Biotherapeutics (BRNS), Oramed Pharmaceuticals (ORMP), Cellectar Biosciences (CLRB), Seres Therapeutics (MCRB), Genelux (GNLX), and InterCure (INCR). These companies are all part of the "pharmaceutical preparations" industry.
Cartesian Therapeutics (NASDAQ:RNAC) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.
IO Biotech has a net margin of 0.00% compared to IO Biotech's net margin of -845.01%. IO Biotech's return on equity of -58.21% beat Cartesian Therapeutics' return on equity.
Cartesian Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.
IO Biotech has lower revenue, but higher earnings than Cartesian Therapeutics.
Cartesian Therapeutics currently has a consensus target price of $45.00, suggesting a potential upside of 115.31%. IO Biotech has a consensus target price of $8.33, suggesting a potential upside of 474.71%. Given Cartesian Therapeutics' higher probable upside, analysts clearly believe IO Biotech is more favorable than Cartesian Therapeutics.
87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 31.2% of Cartesian Therapeutics shares are held by insiders. Comparatively, 3.5% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
IO Biotech received 7 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 86.67% of users gave IO Biotech an outperform vote.
In the previous week, Cartesian Therapeutics had 25 more articles in the media than IO Biotech. MarketBeat recorded 27 mentions for Cartesian Therapeutics and 2 mentions for IO Biotech. IO Biotech's average media sentiment score of 0.70 beat Cartesian Therapeutics' score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media.
Summary
Cartesian Therapeutics beats IO Biotech on 10 of the 14 factors compared between the two stocks.
Get IO Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IO Biotech Competitors List
Related Companies and Tools
